GSK Investigational Site

Samara 443099

0 studies enrolling now · 30 studies all time

What they study most

Acute Coronary Syndrome, Asthma, Cholestasis, Chronic Liver Disease, Colitis, Ulcerative, Crohn's Disease, Depressive Disorder, Major, Diabetes Mellitus, Diabetes Mellitus, Type 2, Epilepsy, Partial, Epilepsy, Tonic-Clonic, HBV

Studies at this site

• Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) — Running, not enrolling
• Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure) — Running, not enrolling
• Linerixibat Long-term Safety, and Tolerability Study — Running, not enrolling
• Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma — Running, not enrolling
• Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma — Completed
• A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults — Stopped early
• Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB) — Completed
• A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB) — Completed
• Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis — Stopped early
• A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma — Completed
• Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma — Completed
• Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma — Completed
• Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus — Completed
• Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures — Stopped early
• A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy. — Completed
• An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease — Stopped early
• A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting. — Completed
• Clinical Study to Test a New Drug to Treat Major Depression — Completed
• Open-Label Extension Study of GSK1605786A — Stopped early
• GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease — Stopped early
• The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial — Completed
• A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60) — Completed
• Study In People With Type 2 Diabetes — Completed
• LENS - Long-term Eltrombopag Observational Study — Completed
• Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy — Completed
• Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures — Completed
• A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease — Completed
• Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting — Completed